Adam Schechter Sells 4,669 Shares of Labcorp (NYSE:LH) Stock

Labcorp Holdings Inc. (NYSE:LH) CEO Adam Schechter sold 4,669 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the sale, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Price Performance

LH stock opened at $322.73 on Friday. The stock has a 50-day moving average price of $285.20 and a two-hundred day moving average price of $274.37. The stock has a market cap of $26.17 billion, a PE ratio of 26.69, a price-to-earnings-growth ratio of 1.87 and a beta of 0.87. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $325.58.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities analysts forecast that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a $0.72 dividend. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s payout ratio is presently 23.82%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LH shares. Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Mizuho set a $355.00 price objective on shares of Labcorp in a research report on Monday. Bank of America increased their target price on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Morgan Stanley raised their target price on shares of Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Truist Financial lifted their price target on shares of Labcorp from $320.00 to $350.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $330.00.

Institutional Investors Weigh In On Labcorp

Large investors have recently made changes to their positions in the stock. REAP Financial Group LLC increased its holdings in Labcorp by 20.4% during the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after buying an additional 37 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after acquiring an additional 40 shares during the last quarter. Hilltop Holdings Inc. grew its position in shares of Labcorp by 2.6% in the 4th quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 41 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of Labcorp by 3.9% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock worth $282,000 after purchasing an additional 42 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of Labcorp by 37.5% during the 3rd quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after purchasing an additional 42 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.